Questions to Ask Your Doctor About Tysabri and PML Risk in Florida

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Education to Occupational Risk Awareness

If you or a loved one has taken Tysabri and are concerned about the risk of progressive multifocal leukoencephalopathy (PML), you likely have many questions about what the future holds. The medical community has long recognized that understanding long-term outcomes is essential for informed decision-making. This page outlines key follow-up questions to discuss with your healthcare provider regarding PML monitoring and prognosis.

Tysabri and the Risk of Progressive Multifocal Leukoencephalopathy

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease in adults. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. The U.S. Food and Drug Administration (FDA) has assigned a boxed warning to Tysabri, stating that the drug 'increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability' (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This warning is the highest level of safety alert for a prescription medication. The clinical presentation of PML is variable but typically includes subacute neurological deficits such as cognitive impairment, motor weakness, gait disturbance, visual field defects, and speech difficulties. Diagnosis relies on brain magnetic resonance imaging showing characteristic white matter lesions and detection of JC virus DNA in cerebrospinal fluid. The disease progresses rapidly and often leads to permanent disability or death. The FDA label notes that PML 'usually leads to death or severe disability' (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Mechanism of PML and Risk Factors

The mechanistic pathway linking Tysabri to PML involves the drug's action as an alpha-4 integrin antagonist. Tysabri blocks the adhesion molecule VLA-4 on lymphocytes, preventing their migration across the blood-brain barrier into the central nervous system. This immunosuppressive effect reduces immune surveillance in the brain, allowing latent JC virus to reactivate and cause lytic infection of oligodendrocytes. The FDA label identifies three established risk factors for PML in Tysabri-treated patients: 'the presence of anti-JCV antibodies, duration of therapy, and prior use of immunosuppressants' (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk, and the risk increases with longer treatment duration, especially beyond two years. Prior use of immunosuppressants further elevates the risk. The adequacy of warnings regarding Tysabri and PML is a central issue in legal claims. The FDA label includes a boxed warning that instructs healthcare professionals to 'monitor patients on TYSABRI for any new sign or symptom that may be suggestive of PML' and to 'withhold TYSABRI dosing immediately at the first sign or symptom suggestive of PML' (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The drug is also available only through a restricted distribution program called the TOUCH Prescribing Program, which aims to ensure that patients and prescribers are aware of the PML risk.

Statute of Limitations for Tysabri Claims in Florida

For patients affected by Tysabri-associated PML, attorney-related considerations include the statute of limitations for filing a claim in Florida. In Florida, the statute of limitations for personal injury actions, including product liability claims, is generally two years from the date the injury was discovered or should have been discovered with reasonable diligence. For PML, the timeline between exposure to Tysabri and documented harm can be variable. PML typically develops after months to years of treatment, with the risk increasing beyond two years of therapy. The FDA label states that 'longer treatment duration, especially beyond 2 years' is a known risk factor (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The onset of symptoms may be insidious, and diagnosis can be delayed, which may affect the date of discovery for statute of limitations purposes. Adverse event reports submitted to the FDA Adverse Event Reporting System (FAERS) provide additional context. The most frequently reported adverse events associated with Tysabri include fatigue, multiple sclerosis relapse, headache, gait disturbance, fall, memory impairment, asthenia, balance disorder, hypoesthesia, muscular weakness, cognitive disorder, and mobility decreased (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these reports do not confirm causation, they reflect the range of neurological and systemic symptoms that may be reported by patients, some of which could overlap with early signs of PML.

Legal Recourse and Timely Action

In summary, Tysabri carries a known risk of PML, a severe and often fatal brain infection. The FDA label provides clear warnings about this risk and identifies specific factors that increase the likelihood of PML. For patients in Florida who have developed PML after Tysabri treatment, legal claims must be filed within the applicable statute of limitations, which is typically two years from discovery of the injury. The timeline between drug exposure and harm can be prolonged, and early symptoms may be subtle, underscoring the importance of timely medical evaluation and legal consultation. References - https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962 - https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in Florida?

In Florida, the statute of limitations for personal injury claims, including product liability, is generally two years from the date the injury was discovered or should have been discovered. For PML, the discovery date may be delayed due to the insidious onset of symptoms.

What are the risk factors for PML in Tysabri patients?

The FDA label identifies three established risk factors: presence of anti-JCV antibodies, duration of therapy (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.